The Wall Street Journal slammed Donald Trump’s new plan to expand drug price controls, calling it his “worst idea since tariffs.”
In a fiery editorial, the conservative newspaper pulled no punches, warning that Trump’s latest move could do serious damage. “President Trump and Republicans appear to be shrinking from reforming Medicaid, but that’s not the worst of it,” the Journal wrote. “To replace the spending slowdown they won’t get in Medicaid, they may expand drug price controls. For that trade we could have elected Democrats.”
Trump’s team wants Medicaid to start paying the lowest price that drug companies charge in other developed countries. The idea is to save money—possibly up to $880 billion, according to the White House.
But the Journal isn’t buying it. The editorial board said any savings would be “negligible,” and warned the plan would actually hurt Americans. It would “harm innovation and raise prices for Americans with private insurance,” the paper argued.
This isn’t the first time the Wall Street Journal has gone after Trump’s economic ideas. The paper has long criticized his tariffs — but this time, it says, he’s gone even further.
“Worst idea since tariffs,” the Rupert Murdoch-owned newspaper declared in its headline.
Trump’s drug pricing plan is a mistake, and the warning is coming from one of the most influential conservative voices in the country.
Read the full editorial here.
